With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG.... Jun 14
Compugen Ltd expands collaboration agreement with Bristol Myers Squibb with phase 1b combination study of COM701 with opdivo C... Feb 22
European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer.... Nov 02
Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today declared their 4th and full year report.... Feb 21
-Advertisements-